Cancer Immunology Reserch

Cancer Immunol Res. 2025 Dec 5. doi: 10.1158/2326-6066.CIR-25-0514. Online ahead of print. ABSTRACT Adoptive transfer of T lymphocytes specific for tumor-associated neoantigens can elicit immunity against solid tumors in patients. However, how these antigens impact T cell function, effector differentiation, and persistence remains unclear. We examined how an identical CD8+ T cell product was shaped … Read more

Cancer Immunol Res. 2025 Dec 2;13(12):1893. doi: 10.1158/2326-6066.CIR-13-12-WWR. NO ABSTRACT PMID:41327976 | DOI:10.1158/2326-6066.CIR-13-12-WWR

Cancer Immunol Res. 2025 Dec 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-25-0631. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of cancer. However, the durable response to this therapy remains low, and there is a risk of moderate-to-severe toxicities following treatment that requires close monitoring. Over the past decade, we have learned … Read more

Cancer Immunol Res. 2025 Nov 26. doi: 10.1158/2326-6066.CIR-25-0444. Online ahead of print. ABSTRACT Treatment of melanoma with BRAF inhibitors plus MEK inhibitors (BRAFi + MEKi) stimulates an intratumoral immune response, in part through pyroptosis mediated by the pore-forming protein gasdermin E (GSDME/Gsdme). How GSDME mediates effects on tumoral immunity is not well characterized. Using single-cell … Read more

Cancer Immunol Res. 2025 Nov 21. doi: 10.1158/2326-6066.CIR-25-0756. Online ahead of print. ABSTRACT Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. Here we identify … Read more

Cancer Immunol Res. 2025 Nov 21. doi: 10.1158/2326-6066.CIR-25-0168. Online ahead of print. ABSTRACT Large parallel genetic screens have been used to identified targets and regulators that enhance T cell antitumor capability and persistence in tumor microenvironment. We hypothesized that by combining the pooled screen data from multiple independent genetic screens we could provide a systematic, … Read more

Cancer Immunol Res. 2025 Nov 21. doi: 10.1158/2326-6066.CIR-25-0445. Online ahead of print. ABSTRACT Tissue-resident memory T (TRM) cells, memory T cells that stably occupy tissues and contribute to immunosurveillance, induce favorable survival outcomes in solid tumors. While TRM cells have been observed in lymph nodes, their phenotype and prognostic significance in diffuse large B-cell lymphoma … Read more

Cancer Immunol Res. 2025 Nov 18. doi: 10.1158/2326-6066.CIR-25-0625. Online ahead of print. ABSTRACT The activity of bispecific antibodies against vascular endothelial growth factor (VEGF) and programmed death ligand-1 (PD-1) have reinvigorated interest in dual VEGF and PD-1 targeting across solid tumors. However, the tumor and immune features influencing tumor response remain largely unknown. We conducted … Read more

Cancer Immunol Res. 2025 Nov 14. doi: 10.1158/2326-6066.CIR-25-0454. Online ahead of print. ABSTRACT Invariant Natural Killer T (iNKT) cells are a conserved T lymphocyte population capable of acting on dendritic cells (DCs) to potently amplify downstream immune responses. However, the processes underlying such iNKT adjuvancy remain poorly understood. Here, we showed that allogeneic human CD4+ … Read more

Cancer Immunol Res. 2025 Nov 14. doi: 10.1158/2326-6066.CIR-25-0349. Online ahead of print. ABSTRACT Cellular immunotherapies show remarkable efficacy against hematological malignancies. However, applying these therapies against solid tumors is challenging. Among the obstacles are the lack of tumor-specific antigens and the immunosuppressive tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) are key … Read more